Abstract
Mucopolysaccharidosis I (MPS I) is a genetic disorder caused by mutations on α-L-iduronidase (IDUA) gene, leading to low or null enzyme activity. As nonsense mutations are present in about two thirds of the patients, stop codon read through (SCRT) is a potential alternative to achieve enhanced enzyme activity. This mechanism suppresses premature stop codon mutations allowing the protein to be fully translated. Chloramphenicol is a peptidyl transferase inhibitor able to induce readthrough and is efficient in cross the blood brain barrier. In this work, fibroblasts from MPS I patients (p.W402X/p.W402X; p.R89W/p.W402X and p.Q70X/c.1739-1g>t) were treated with chloramphenicol, which resulted in 100-fold increase on IDUA activity on compound heterozygous fibroblasts. cDNA sequencing showed that only the alleles without the nonsense mutation were being amplified, even after treatment, leading us to suggest that the nonsense alleles were targeted to nonsense-mediated mRNA decay and that chloramphenicol acts through a mechanism other than SCRT.
Keywords: Alpha-l-iduronidase, Chloramphenicol, Mucopolysaccharidosis I, Nonsense Mediated RNA Decay, premature stop codon mutations, stop codon read through
Current Pharmaceutical Biotechnology
Title:Chloramphenicol Enhances IDUA Activity on Fibroblasts from Mucopolysaccharidosis I Patients
Volume: 14 Issue: 2
Author(s): Fabiana Quoos Mayer, Osvaldo Alfonso Artigalas, Valeska Lizzi Lagranha, Guilherme Baldo, Ida Vanessa Schwartz, Ursula Matte and Roberto Giugliani
Affiliation:
Keywords: Alpha-l-iduronidase, Chloramphenicol, Mucopolysaccharidosis I, Nonsense Mediated RNA Decay, premature stop codon mutations, stop codon read through
Abstract: Mucopolysaccharidosis I (MPS I) is a genetic disorder caused by mutations on α-L-iduronidase (IDUA) gene, leading to low or null enzyme activity. As nonsense mutations are present in about two thirds of the patients, stop codon read through (SCRT) is a potential alternative to achieve enhanced enzyme activity. This mechanism suppresses premature stop codon mutations allowing the protein to be fully translated. Chloramphenicol is a peptidyl transferase inhibitor able to induce readthrough and is efficient in cross the blood brain barrier. In this work, fibroblasts from MPS I patients (p.W402X/p.W402X; p.R89W/p.W402X and p.Q70X/c.1739-1g>t) were treated with chloramphenicol, which resulted in 100-fold increase on IDUA activity on compound heterozygous fibroblasts. cDNA sequencing showed that only the alleles without the nonsense mutation were being amplified, even after treatment, leading us to suggest that the nonsense alleles were targeted to nonsense-mediated mRNA decay and that chloramphenicol acts through a mechanism other than SCRT.
Export Options
About this article
Cite this article as:
Quoos Mayer Fabiana, Alfonso Artigalas Osvaldo, Lizzi Lagranha Valeska, Baldo Guilherme, Vanessa Schwartz Ida, Matte Ursula and Giugliani Roberto, Chloramphenicol Enhances IDUA Activity on Fibroblasts from Mucopolysaccharidosis I Patients, Current Pharmaceutical Biotechnology 2013; 14 (2) . https://dx.doi.org/10.2174/1389201011314020009
DOI https://dx.doi.org/10.2174/1389201011314020009 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Prospective Teratology of Retinoic Acid Metabolic Blocking Agents (RAMBAs) and Loss of CYP26 Activity
Current Pharmaceutical Design Molecular Docking Study of a Series of Substituted Xanthone Derivatives as Novel COX-2 Inhibitors Targeting Prostaglandin Endoperoxide Synthase -2
Current Enzyme Inhibition Alphavirus Vectors for Gene Therapy Applications
Current Gene Therapy Regulation of Apoptosis by Gram-Positive Bacteria: Mechanistic Diversity and Consequences for Immunity
Current Immunology Reviews (Discontinued) Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects
Current Pharmaceutical Design Serratia Type Pore Forming Toxins
Current Protein & Peptide Science Glycodendrimers as Anti-Adhesion Drugs Against Type 1 Fimbriated E. coli Uropathogenic Infections
Mini-Reviews in Medicinal Chemistry The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Delivery Systems of Opioid Analgesics for Pain Relief: A Review
Current Pharmaceutical Design Diagnostic Value of the Leukocyte Esterase Test for Early Detection of Pleocytosis in Cerebrospinal Fluid of Patients with Suspected Acute Bacterial Meningitis
Infectious Disorders - Drug Targets Viruses and Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets Neuropsychiatric Systemic Lupus Erythematosus
Current Neuropharmacology New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas
Current Pharmaceutical Design Re-Examining the Need for Tissue Diagnosis in Pediatric Diffuse Intrinsic Pontine Gliomas: A Review
Current Neuropharmacology Innovations and Opportunities to Improve Conventional (Deoxy)Nucleoside and Fluoropyrimidine Analogs in Cancer
Current Medicinal Chemistry Immune Checkpoint Inhibitors and Neurotoxicity
Current Neuropharmacology Laboratory Diagnosis and Therapy of Invasive Fungal Infections
Current Drug Targets Challenges and Opportunities for Bacterial Vaccine Development in the 21<sup>st</sup> Century
Current Pharmaceutical Biotechnology In Vivo Imaging of the Diseased Nervous System: An Update
Current Pharmaceutical Design Aptamers: Molecular Tools for Medical Diagnosis
Current Topics in Medicinal Chemistry